Inactivating mutations in Keap1 have been reported to induce several cancers, including breast cancer and non-small cell lung carcinoma (NSCLC), as well as squamous cell lung carcinomas (SCLCs), further actuating the tumorigenicity and resistance to chemotherapy [102,103]. The gene discussed is KEAP1; the disease is non-small cell lung carcinoma.